Skip to main content

Table 1 Cardiovascular results of the Empa-Reg outcome study

From: The EMPA-REG outcome study: critical appraisal and potential clinical implications

 

Empagliflozin (all together)

Placebo

HR 95 % CI

Non inferiority

Superiority

Primary endpoint

490/4687 (10.5 %)

282/2333 (12.1 %)

0.86

0.74–0.99

P < 0.001

P = 0.04

Key secondary endpoint

599/4687 (12.8 %)

333/2333 (14.3 %)

0.89

0.78–1.01

P < 0.001

P = 0.08

 Cardiovascular death

172/4687 (3.7 %)

137/2333 (5.9 %)

0.62

0.49–0.77

N.A.

P < 0.001

 Non-fatal myocardial infarction

213/4687 (4.5 %)

121/2333 (5.2 %)

0.87

0.70–1.09

N.A.

P = 0.22

 Non-fatal stroke

150/4687 (3.2 %)

60/2333 (2.6 %)

1.24

0.92–1.67

N.A.

P = 0.16

Heart failure

126/4687 (2.7 %)

95/2333 (4.1 %)

0.65

0.50–0.85

N.A.

P = 0.002

All-cause death

269/4687 (5.7 %)

194/2333 (8.3 %)

0.68

0.57–0.82

N.A.

P = 0.001

  1. Primary endpoint: standard 3 endpoint-MACE (CV death, non-fatal myocardial infarction (MI), non-fatal stroke); pre-specified key secondary endpoints: time to first event (CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina)
  2. N.A. not applicable